Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22484651 | 0.86 | L3MBTL1 (0.53) | L3MBTL1OPRK1AKR1C3MEN1KMT2A | |
| SCHEMBL20047167 | 0.83 | L3MBTL1 (0.50) | L3MBTL1OPRK1AKR1C3MEN1KMT2A | |
| SCHEMBL19748736 | 0.82 | L3MBTL1 (0.49) | L3MBTL1OPRK1AKR1C3MEN1KMT2A | |
| SCHEMBL20047172 | 0.81 | TMEM97 (0.51) | L3MBTL1OPRK1AKR1C3MEN1KMT2A | |
| SCHEMBL20047016 | 0.81 | L3MBTL1 (0.46) | L3MBTL1OPRK1AKR1C3MEN1KMT2A | |
| SCHEMBL20047233 | 0.80 | L3MBTL1 (0.47) | L3MBTL1OPRK1AKR1C3MEN1KMT2A | |
| SCHEMBL20047232 | 0.80 | AKR1C3 (0.49) | L3MBTL1OPRK1AKR1C3MEN1KMT2A | |
| SCHEMBL20047168 | 0.79 | OPRK1 (0.53) | L3MBTL1OPRK1AKR1C3MEN1KMT2A | |
| SCHEMBL20047176 | 0.79 | CYP11B1 (0.52) | L3MBTL1OPRK1 | |
| SCHEMBL20047174 | 0.78 | L3MBTL1 (0.46) | L3MBTL1OPRK1AKR1C3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2017223514-A9 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | NR1H2, NR1H3, PPARD | L3MBTL1 1781/4885OPRK1 746/4885AKR1C3 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.